Evidence map›Paper›PMID 36163612›Full record

ArticleJournal of orthopaedic research : official publication of the Orthopaedic Research Society2023

Trabecular bone microcrack accumulation in patients treated with bisphosphonates for durations up to 16 years.

David Pienkowski, Constance L Wood, Hartmut H Malluche

Open access · greenAbstract read
In one paragraph

Article in Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. [Comprehensive considerations for the diagnosis, treatment, and management of osteogenesis imperfecta].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2025
    Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

David PienkowskiF. Joseph Halcomb III, MD Department of Biomedical Engineering, University of Kentucky, Lexington, Kentucky, USA.
Constance L WoodDepartment of Statistics, University of Kentucky, Lexington, Kentucky, USA.
Hartmut H MallucheDepartment of Medicine, Division of Nephrology, Bone & Mineral Metabolism, University of Kentucky, Lexington, Kentucky, USA.ORCID 0000-0002-5604-9941
University of Kentucky · US

Funding

BISPHOSPHONATE USE AND BONE QUALITYR01AR061578 · NIAMS · UNIVERSITY OF KENTUCKY · PI MALLUCHE, HARTMUT H · 2012 to 2015
$1.4M
NIAMS NIH HHS R01 AR061578
6 · The paper itself

Abstract

This study quantified the length, number, and density of microcracks in bone from patients treated with bisphosphonates as a function of duration. Anterior iliac crest bone samples from 51 osteoporotic Caucasian females continuously treated with oral bisphosphonates for 1-16 years were obtained by bone biopsy. Samples were histologically processed and analyzed for bone area, microcrack number, and microcrack length. The analyses used statistical modeling and considered patient age, bone mineral density, bone volume/total volume, trabecular thickness, and bone turnover as potential covariates. Microcrack density (number of microcracks/total examined bone area) was linearly related (p = 0.018) to bisphosphonate treatment duration. None of the analyzed covariates contributed significantly to the observed relationship between microcrack density and bisphosphonate treatment duration. Observed increases in microcrack density with increasing bisphosphonate treatment duration is important because increasing levels of microcracks may not only affect bone remodeling but also reduce elastic modulus and are suspected to adversely affect other mechanical properties that may influence fracture risk. The present findings add to our prior results showing changes in bone material properties and modulus with bisphosphonate treatment duration and thereby provide a more comprehensive assessment of the relationship between bisphosphonate treatment duration and bone quality. Statement of Clinical Significance: The present findings provide information guiding clinical use of oral bisphosphonates for post-menopausal osteoporosis therapy.

Indexed as

DiphosphonatesFractures, BoneBone and BonesBone DensityCancellous BoneFemaleHumansDiphosphonatesbisphosphonatesbone biopsybone qualitymicrocracksosteoporosis therapy

Identifiers

PMID36163612
PMCPMC10039958
OpenAlexW4297251948

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.